{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:56:45Z","timestamp":1787021805386,"version":"build-2736575974"},"reference-count":107,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1002873","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T13:22:17Z","timestamp":1568121737000},"page":"e1002873","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":67,"title":["The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011\u20132018"],"prefix":"10.1371","volume":"16","author":[{"given":"Catherine","family":"Schuster Bruce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2085-0304","authenticated-orcid":true,"given":"Petra","family":"Brhlikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9757-9754","authenticated-orcid":true,"given":"Patricia","family":"McGettigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"key":"pmed.1002873.ref001","unstructured":"European Medicines Agency. About Us page. Available from: https:\/\/www.ema.europa.eu\/en\/about-us\/who-we-are [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref002","unstructured":"European Medicines Agency. Support for early access. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/support-early-access. [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref003","unstructured":"European Medicines Agency. Conditional Marketing Authorisation. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/conditional-marketing-authorisation. [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref004","unstructured":"The Commission of the European Communities. Commission Regulation (EC) No 507\/2006 of 29 March 2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726\/2004 of the European Parliament and of the Council. Available from: https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-1\/reg_2006_507\/reg_2006_507_en.pdf. [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref005","unstructured":"European Medicines Agency. Accelerated Assessment. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/accelerated-assessment. [cited 2019 Aug 19]."},{"issue":"8","key":"pmed.1002873.ref006","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ejim.2015.08.008","article-title":"Approvals of drugs with uncertain benefit\u2013risk profiles in Europe","volume":"26","author":"R Banzi","year":"2015","journal-title":"Eur J Intern Med"},{"issue":"25","key":"pmed.1002873.ref007","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"TR Fleming","year":"2012","journal-title":"Stat Med"},{"issue":"3","key":"pmed.1002873.ref008","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","article-title":"Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward","volume":"20","author":"O Ciani","year":"2017","journal-title":"Value Health"},{"issue":"3","key":"pmed.1002873.ref009","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1017\/S0266462314000300","article-title":"Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers","volume":"30","author":"O. Ciani","year":"2014","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"pmed.1002873.ref010","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology","volume":"106","author":"A Haslam","year":"2019","journal-title":"Eur J Cancer"},{"key":"pmed.1002873.ref011","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"R Kemp","year":"2017","journal-title":"BMC Medicine"},{"issue":"8","key":"pmed.1002873.ref012","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"V Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"3","key":"pmed.1002873.ref013","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1017\/S0266462318000338","article-title":"Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology","volume":"34","author":"K Hernandez-Villafuerte","year":"2018","journal-title":"Int J Technol Assess Health Care"},{"key":"pmed.1002873.ref014","doi-asserted-by":"crossref","first-page":"d7995","DOI":"10.1136\/bmj.d7995","article-title":"The idolatry of the surrogate","volume":"343","author":"J Yudkin","year":"2011","journal-title":"BMJ"},{"key":"pmed.1002873.ref015","unstructured":"European Medicines Agency. Conditional Marketing Authorisation: Report on ten years of experience at the European Medicines Agency. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/report\/conditional-marketing-authorisation-report-ten-years-experience-european-medicines-agency_en.pdf. [cited 2019 Aug 19]."},{"issue":"5","key":"pmed.1002873.ref016","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamainternmed.2018.8351","article-title":"Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials","volume":"179","author":"EY Chen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"pmed.1002873.ref017","doi-asserted-by":"crossref","first-page":"h4633","DOI":"10.1136\/bmj.h4633","article-title":"Trends in utilization of FDA expedited drug development and approval programs, 1987\u20132014: cohort study","volume":"351","author":"AS Kesselheim","year":"2015","journal-title":"BMJ"},{"key":"pmed.1002873.ref018","unstructured":"US FDA. Center for drug evaluation and research: Advancing health through innovation: 2017 new drug therapy approvals. January 2018. Available from: https:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ReportsBudgets\/UCM591976.pdf. [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref019","unstructured":"European Medicines Agency: Medicines. Available from: https:\/\/www.ema.europa.eu\/en\/medicines. [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref020","unstructured":"European Medicines Agency. Annual Report 2018. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-annual-report-2018-published. [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref021","unstructured":"European Medicines Agency. Exceptional circumstances. Available from: https:\/\/www.ema.europa.eu\/en\/glossary\/exceptional-circumstances. [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref022","unstructured":"European Medicines Agency. Qualification of novel methodologies for medicine development. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/scientific-advice-protocol-assistance\/qualification-novel-methodologies-medicine-development. [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref023","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1377\/hlthaff.24.1.67","article-title":"Surrogate endpoints and FDA\u2019s accelerated approval process","volume":"24","author":"TR Fleming","year":"2005","journal-title":"Health Affairs"},{"key":"pmed.1002873.ref024","article-title":"Assessment of clinical benefit of cancer drugs receiving accelerated approval","author":"B Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"key":"pmed.1002873.ref025","article-title":"An overview of cancer drugs approved by the US Food and Drug Administration based on surrogate endpoint of response rate","author":"EY Chen","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"7","key":"pmed.1002873.ref026","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jama.2017.9415","article-title":"Characteristics of pre-approval and post-approval studies for drugs granted accelerated approval by the US Food and Drug Administration","volume":"318","author":"H Naci","year":"2017","journal-title":"JAMA."},{"issue":"6","key":"pmed.1002873.ref027","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: A review","volume":"4","author":"JA Beaver","year":"2018","journal-title":"JAMA Oncol"},{"key":"pmed.1002873.ref028","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: Retrospective cohort study of drug approvals 2009\u201313","volume":"359","author":"C Davis","year":"2017","journal-title":"BMJ"},{"key":"pmed.1002873.ref029","unstructured":"Anon. Lilly reports results of Phase 3 soft tissue sarcoma study of Lartruvo. Available from: http:\/\/lilly.mediaroom.com\/index.php?s=9042&item=137861. [cited 2019 Jan 18]."},{"key":"pmed.1002873.ref030","unstructured":"EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo [press release 2019 April 26]. European Medicines Agency c1995-2018. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-withdrawal-marketing-authorisation-cancer-medicine-lartruvo. [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref031","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical evaluation of direct acting antivirals for the treatment of chronic hepatitis. EMEA\/CHMP\/EWP\/30039\/2008 Rev 1. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-clinical-evaluation-direct-acting-antivirals-treatment-chronic-hepatitis_en.pdf. [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref032","article-title":"Direct\u2010acting antivirals for chronic hepatitis C","volume":"9","author":"JC Jakobsen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"pmed.1002873.ref033","article-title":"Do direct acting antivirals cure chronic hepatitis C?","volume":"361","author":"JC Jakobson","year":"2018","journal-title":"BMJ"},{"key":"pmed.1002873.ref034","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.29811","article-title":"Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease","volume":"68","author":"LI Backus","year":"2018","journal-title":"Hepatology"},{"key":"pmed.1002873.ref035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hep.29408","article-title":"Direct-acting antiviral sustained virologic response: Impact on mortality in patients with advanced liver disease","volume":"69","author":"LI Backus","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"pmed.1002873.ref036","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcf.2017.01.002","article-title":"Use of FEV1 in Cystic Fibrosis Epidemiologic Studies and Clinical Trials: A statistical perspective for the clinical researcher","volume":"16","author":"R Szczesniak","year":"2017","journal-title":"J Cyst Fibros"},{"key":"pmed.1002873.ref037","unstructured":"European Medicines Agency. Report of the workshop on endpoints for cystic fibrosis clinical trials. (2012) EMA\/769571\/2012]."},{"issue":"4","key":"pmed.1002873.ref038","doi-asserted-by":"crossref","first-page":"e0125403","DOI":"10.1371\/journal.pone.0125403","article-title":"Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: Model validation and update","volume":"10","author":"RS Wallis","year":"2015","journal-title":"PLoS ONE"},{"key":"pmed.1002873.ref039","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1164\/rccm.201508-1546OC","article-title":"Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis","volume":"194","author":"B Ley","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"pmed.1002873.ref040","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1164\/rccm.201105-0840OC","article-title":"Forced vital capacity in patients with idiopathic pulmonary fibrosis test properties and minimal clinically important difference","volume":"184","author":"RM du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"pmed.1002873.ref041","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jns5.12059","article-title":"Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy","volume":"19","author":"EJ Vinik","year":"2014","journal-title":"J Peripheral NS"},{"issue":"5","key":"pmed.1002873.ref042","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/mus.25563","article-title":"Assessing mNIS+7Ionis and international neurologists\u2019 profiency in a FAP trial","volume":"56","author":"PJ Dyck","year":"2017","journal-title":"Muscle Nerve"},{"key":"pmed.1002873.ref043","article-title":"Strength of validation for surrogate end points used in the us food and drug administration\u2019s approval of oncology drugs","author":"C Kim","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"pmed.1002873.ref044","doi-asserted-by":"crossref","first-page":"e180416","DOI":"10.1001\/jamanetworkopen.2018.0416","article-title":"A comparison of response patterns for progression-free survival and overall survival following treatment for cancer with PD-1 Inhibitors: A meta-analysis of correlation and differences in effect sizes","volume":"1","author":"B Gyawali","year":"2018","journal-title":"JAMA Netw Open"},{"key":"pmed.1002873.ref045","first-page":"66","article-title":"Five years of EMA-approved systemic cancer therapies for solid tumours\u2014a comparison of two thresholds for meaningful clinical benefit","volume":"82","author":"N Gr\u00f6ssmann","year":"2017","journal-title":"EurJCan"},{"key":"pmed.1002873.ref046","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1: Update and clarification","volume":"62","author":"RECIST Committee","year":"2016","journal-title":"Eur J Cancer"},{"key":"pmed.1002873.ref047","unstructured":"EMA. Guideline on the evaluation of anticancer medicinal products in man (with Appendix 1) 22 September 2017; EMA\/CHMP\/205\/95\/Rev.5. Available from: https:\/\/www.ema.europa.eu\/en\/evaluation-anticancer-medicinal-products-man. [cited ]."},{"key":"pmed.1002873.ref048","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref049","unstructured":"EUnetHTA. Endpoints used in relative effectiveness assessment of pharmaceuticals: Surrogate endpoints. 2013. Available from: https:\/\/www.eunethta.eu\/wp-content\/uploads\/2018\/01\/Surrogate-Endpoints.pdf. [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref050","unstructured":"Institute for Quality and Efficiency in Healthcare (IQWiG). Validity of surrogate endpoints in oncology. Rapid Report A10-05. 2011. Available from: https:\/\/www.iqwig.de\/en\/projects-results\/projects\/drug-assessment\/a10-05-validity-of-surrogate-endpoints-in-oncology-rapid-report.1325.html. [cited 2019 Aug 19]."},{"key":"pmed.1002873.ref051","doi-asserted-by":"crossref","first-page":"l4340","DOI":"10.1136\/bmj.l4340","article-title":"New drugs: Where did we go wrong and what can we do better?","volume":"366","author":"B Weisler","year":"2019","journal-title":"BMJ"},{"issue":"8","key":"pmed.1002873.ref052","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1377\/hlthaff.2016.1541","article-title":"Drugs cleared through the FDA\u2019s expedited review offer greater gains than drugs approved by conventional process","volume":"36","author":"JD Chalmers","year":"2017","journal-title":"Health Affairs"},{"issue":"3","key":"pmed.1002873.ref053","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2125.2011.03995.x","article-title":"Additional safety risk to exceptionally approved drugs in Europe?","volume":"72","author":"AH Arnardottir","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"pmed.1002873.ref054","doi-asserted-by":"crossref","first-page":"j2062","DOI":"10.1136\/bmj.j2062","article-title":"Conditional approval of medicines by the EMA","volume":"357","author":"R Banzi","year":"2017","journal-title":"BMJ"},{"key":"pmed.1002873.ref055","doi-asserted-by":"crossref","first-page":"e020377","DOI":"10.1136\/bmjopen-2017-020377","article-title":"Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study","volume":"8","author":"J Lexchin","year":"2018","journal-title":"BMJ Open"},{"key":"pmed.1002873.ref056","first-page":"213","article-title":"Characteristics and follow\u2010up of postmarketing studies of conditionally authorized medicines in the EU","volume":"82","author":"J Hoekman","year":"2016","journal-title":"BrJClinPharmacol"},{"key":"pmed.1002873.ref057","unstructured":"Fampyra https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/fampyra-epar-public-assessment-report_en.pdf (First published: 04\/08\/2011; Last updated: 04\/08\/2011). [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref058","unstructured":"Votubia https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/votubia-epar-public-assessment-report_en.pdf (First published: 19\/09\/2011; Last updated: 19\/09\/2011). [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref059","unstructured":"Caprelsa https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/caprelsa-epar-public-assessment-report_en.pdf (First published: 02\/03\/2012; Last updated: 02\/03\/2012). [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref060","unstructured":"Pixuvri https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/pixuvri-epar-public-assessment-report_en.pdf (First published: 31\/05\/2012; Last updated: 31\/05\/2012). [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref061","unstructured":"Xalkori https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/xalkori-epar-public-assessment-report_en.pdf (First published: 14\/11\/2012; Last updated: 14\/11\/2012). [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref062","unstructured":"Adcetris https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/adcetris-epar-public-assessment-report_en.pdf (First published: 22\/11\/2012; Last updated: 22\/11\/2012). [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref063","unstructured":"Bosulif https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/bosulif-epar-public-assessment-report_en.pdf (First published: 09\/04\/2013; Last updated: 09\/04\/2012). [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref064","unstructured":"Erivedge https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/erivedge-epar-public-assessment-report_en.pdf (First published: 30\/07\/2013; Last updated: 30\/07\/2013) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref065","unstructured":"Sirturo https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/sirturo-epar-public-assessment-report_en.pdf (First published: 14\/03\/2014; Last updated: 14\/03\/2014) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref066","unstructured":"Cometriq https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/cometriq-epar-public-assessment-report_en.pdf (First published: 26\/03\/2014; Last updated: 26\/03\/2014) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref067","unstructured":"Deltyba https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/deltyba-epar-public-assessment-report_en.pdf (First published: 08\/05\/2014; Last updated: 08\/05\/2014) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref068","unstructured":"Translarna https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/translarna-epar-public-assessment-report_en.pdf (First published: 04\/09\/2014; Last updated: 04\/09\/2014) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref069","unstructured":"Zykadia https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/zykadia-epar-public-assessment-report_en.pdf (First published: 04\/06\/2015; Last updated: 04\/06\/2015) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref070","unstructured":"Blincyto https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/blincyto-epar-public-assessment-report_en.pdf (First published: 07\/12\/2015; Last updated: 07\/12\/2015) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref071","unstructured":"Tagrisso https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/tagrisso-epar-public-assessment-report_en.pdf (First published: 17\/02\/2016; Last updated: 17\/02\/2016) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref072","unstructured":"Darzalex https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/darzalex-epar-public-assessment-report_en.pdf (First published: 27\/05\/2016; Last updated: 27\/05\/2016) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref073","unstructured":"Zalmoxis https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/zalmoxis-epar-public-assessment-report_en.pdf (First published: 05\/09\/2016; Last updated: 05\/09\/2016) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref074","unstructured":"Lartruvo https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/lartruvo-epar-public-assessment-report_en.pdf (First published: 23\/11\/2016; Last updated: 23\/11\/2016) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref075","unstructured":"Ninlaro https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ninlaro-epar-public-assessment-report_en.pdf (First published: 07\/12\/2016; Last updated: 07\/12\/2016) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref076","unstructured":"Venclyxto https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/venclyxto-epar-public-assessment-report_en.pdf (First published: 21\/12\/2016; Last updated: 21\/12\/2016) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref077","unstructured":"Ocaliva https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ocaliva-epar-public-assessment-report_en.pdf (First published: 19\/12\/2016; Last updated: 19\/12\/2016) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref078","unstructured":"Alecensa https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alecensa (First published 11\/04\/2017; Last updated 11\/04\/2017) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref079","unstructured":"Natpar https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/natpar-epar-public-assessment-report_en.pdf (First published: 26\/04\/2017; Last updated: 26\/04\/2017) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref080","unstructured":"Bavencio https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/bavencio-epar-public-assessment-report_en.pdf (First published: 13\/10\/2017; Last updated: 13\/10\/2017) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref081","unstructured":"Crysvita https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/crysvita-epar-public-assessment-report_en.pdf (First published: 12\/03\/2018; Last updated: 12\/03\/2018) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref082","unstructured":"Rubraca https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/rubraca-epar-public-assessment-report_en.pdf (First published: 31\/05\/2018; Last updated: 31\/05\/2018) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref083","unstructured":"Zytiga https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/zytiga-epar-public-assessment-report_en.pdf (First published: 23\/09\/2011; Last updated: 23\/09\/2011) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref084","unstructured":"Zelboraf https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/zelboraf-epar-public-assessment-report_en.pdf (First published: 19\/03\/2012; Last updated: 19\/03\/2012) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref085","unstructured":"Kalydeco https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kalydeco-epar-public-assessment-report_en.pdf (First published: 06\/08\/2012; Last updated: 06\/08\/2012) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref086","unstructured":"Iclusiq https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/iclusig-epar-public-assessment-report_en.pdf (First published: 11\/07\/2013; Last updated: 11\/07\/2013) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref087","unstructured":"Sovaldi https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/sovaldi-epar-public-assessment-report_en.pdf (First published: 05\/02\/2014; Last updated: 05\/02\/2014) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref088","unstructured":"Sylvant https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/sylvant-epar-public-assessment-report_en.pdf (First published: 19\/06\/2014; Last updated: 19\/06\/2014) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref089","unstructured":"Daklinza https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/daklinza-epar-public-assessment-report_en.pdf (First published: 15\/09\/2014; Last updated: 15\/09\/2014) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref090","unstructured":"Harvoni https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/harvoni-epar-public-assessment-report_en.pdf (First published: 04\/12\/2014; Last updated: 04\/12\/2014) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref091","unstructured":"Viekirax https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/viekirax-epar-public-assessment-report_en.pdf (First published: 09\/03\/2015; Last updated: 09\/03\/2015) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref092","unstructured":"Ofev https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ofev-epar-public-assessment-report_en.pdf (First published: 13\/02\/2015; Last updated: 13\/02\/2015) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref093","unstructured":"Exviera https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/exviera-epar-public-assessment-report_en.pdf (First published: 12\/02\/2015; Last updated: 12\/02\/2015) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref094","unstructured":"Lenvima https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/lenvima-epar-public-assessment-report_en.pdf (First published: 25\/06\/2015; Last updated: 25\/06\/2015) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref095","unstructured":"Kanuma https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kanuma-epar-public-assessment-report_en.pdf (First published: 01\/09\/2015; Last updated: 01\/09\/2015) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref096","unstructured":"Kyprolis https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kyprolis-epar-public-assessment-report_en.pdf (First published: 01\/12\/2015; Last updated: 01\/12\/2015) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref097","unstructured":"Empliciti https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/empliciti-epar-public-assessment-report_en.pdf (First published: 19\/05\/2016; Last updated: 19\/05\/2016) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref098","unstructured":"Epclusa https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/epclusa-epar-public-assessment-report_en.pdf (First published: 28\/07\/2016; Last updated: 28\/07\/2016) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref099","unstructured":"Kisplyx https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kisplyx-epar-public-assessment-report_en.pdf (First published: 16\/11\/2016; Last updated: 16\/11\/2016) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref100","unstructured":"Cabometyx https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/cabometyx-epar-public-assessment-report_en.pdf (First published: 12\/10\/2016; Last updated: 12\/10\/2016) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref101","unstructured":"Spinraza https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/spinraza-epar-public-assessment-report_en.pdf (First published: 21\/06\/2017; Last updated: n\/a) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref102","unstructured":"Maviret https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/maviret-epar-public-assessment-report_en.pdf (First published: 17\/08\/2017; Last updated: 17\/08\/2017) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref103","unstructured":"Vosevi https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/vosevi-epar-public-assessment-report_en.pdf (First published: 22\/09\/2017; Last updated: 22\/09\/2017) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref104","unstructured":"Jorveza https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/jorveza-epar-public-assessment-report_en.pdf (First published: 18\/01\/2018; Last updated: 18\/01\/2018) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref105","unstructured":"Tegsedi https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/tegsedi-epar-public-assessment-report_en.pdf (First published: 06\/08\/2018; Last updated: 06\/08\/2018) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref106","unstructured":"Onpattro https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/onpattro-epar-public-assessment-report_.pdf (First published: 30\/10\/2018; Last updated: n\/a) [cited 2019 Jul 23]."},{"key":"pmed.1002873.ref107","unstructured":"Takhzyro https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/takhzyro-epar-public-assessment-report_en.pdf (First published: 17\/12\/2018; Last updated: n\/a) [cited 2019 Jul 23]."}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1002873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T07:47:13Z","timestamp":1589010433000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1002873"}},"subtitle":[],"editor":[{"given":"Aaron S.","family":"Kesselheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":107,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1002873","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]}}}